BC
Birchview Capital Portfolio holdings
AUM
$101M
This Quarter Return
+4.62%
1 Year Return
+34.62%
3 Year Return
+103.2%
5 Year Return
+107.72%
10 Year Return
+352.1%
AUM
$115M
AUM Growth
+$115M
(-6.3%)
Cap. Flow
-$6.8M
Cap. Flow
% of AUM
-5.91%
Top 10 Holdings %
Top 10 Hldgs %
66.12%
Holding
72
New
4
Increased
20
Reduced
12
Closed
4
Top Buys
| 1 |
uniQure
QURE
|
$728K |
| 2 |
OrthoPediatrics
KIDS
|
$493K |
| 3 |
Solid Biosciences
SLDB
|
$476K |
| 4 |
Xenon Pharmaceuticals
XENE
|
$369K |
| 5 |
Prothena Corp
PRTA
|
$351K |
Top Sells
| 1 |
Outset Medical
OM
|
$3.81M |
| 2 |
Karyopharm Therapeutics
KPTI
|
$1.47M |
| 3 |
Acadia Pharmaceuticals
ACAD
|
$1.25M |
| 4 |
Corcept Therapeutics
CORT
|
$914K |
| 5 |
United Therapeutics
UTHR
|
$771K |
Sector Composition
| 1 | Healthcare | 96.33% |
| 2 | Energy | 3.55% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
Bristol-Myers Squibb
BMY
$96B
| $41.8M | 36.29% | 685,192 +10 | +0% | +$610 |
|
|
2
Corcept Therapeutics
CORT
$7.35B
| $7.54M | 6.55% | 66,000 -8,000 | -11% | -$914K |
|
|
3
Acadia Pharmaceuticals
ACAD
$4.38B
| $4.38M | 3.8% | 263,400 -75,000 | -22% | -$1.25M |
|
|
4
Prothena Corp
PRTA
$441M
| $4.12M | 3.58% | 332,974 +28,400 | +9% | +$351K |
|
5
Biodesix
BDSX
$62.6M
| $3.59M | 3.11% | 5,736,113 | – | – |
|
6
Neurocrine Biosciences
NBIX
$13.8B
| $3.34M | 2.9% | 30,240 | – | – |
|
7
Elutia
ELUT
$96.7M
| $3M | 2.61% | 1,187,735 -37,754 | -3% | -$95.5K |
|
8
Axogen
AXGN
$743M
| $2.98M | 2.59% | 161,000 -36,000 | -18% | -$666K |
|
9
Phreesia
PHR
$1.88B
| $2.93M | 2.55% | 114,700 | – | – |
|
10
Travere Therapeutics
TVTX
$1.56B
| $2.47M | 2.15% | 138,000 -10,000 | -7% | -$179K |
|
11
QuidelOrtho
QDEL
$1.95B
| $2.36M | 2.05% | 67,619 | – | – |
|
12
Protagonist Therapeutics
PTGX
$3.67B
| $2.32M | 2.02% | 48,002 +2 | +0% | +$97 |
|
|
13
United Therapeutics
UTHR
$13.8B
| $2.31M | 2.01% | 7,500 -2,500 | -25% | -$771K |
|
14
DocGo
DCGO
$153M
| $2.28M | 1.98% | 864,062 +100,000 | +13% | +$264K |
|
15
Ovintiv
OVV
$10.8B
| $2.23M | 1.94% | 52,200 | – | – |
|
16
Harrow
HROW
$1.44B
| $1.94M | 1.68% | 72,910 | – | – |
|
17
Masimo
MASI
$7.59B
| $1.88M | 1.63% | 11,280 -4,000 | -26% | -$666K |
|
18
EQT Corp
EQT
$32.4B
| $1.85M | 1.61% | 34,619 | – | – |
|
19
Castle Biosciences
CSTL
$696M
| $1.77M | 1.54% | 88,404 +10,404 | +13% | +$208K |
|
20
Alkermes
ALKS
$4.78B
| $1.65M | 1.43% | 50,000 | – | – |
|
21
Stoke Therapeutics
STOK
$1.08B
| $1.4M | 1.21% | 210,005 +5 | +0% | +$33 |
|
22
Treace Medical Concepts
TMCI
$464M
| $1.38M | 1.2% | 164,947 +3,597 | +2% | +$30.2K |
|
23
Foghorn Therapeutics
FHTX
$286M
| $1.13M | 0.99% | 310,930 | – | – |
|
|
24
uniQure
QURE
$896M
| $940K | 0.82% | 88,697 +68,697 | +343% | +$728K |
|
25
KalVista Pharmaceuticals
KALV
$678M
| $773K | 0.67% | 67,002 +2 | +0% | +$23 |
|